Welcome back,

Tag : HEMOPHILIA A

CONFERENCE UPDATE

Unmet needs persist in hemophilia A management: Findings from a real-world analysis of the Adelphi Hemophilia Disease Specific ProgrammeTM
For individuals with hemophilia A, lifelong prophylactic treatment with FVIII replacement therapies or non-factor therapies (NFTs) is the standard of care. Despite advancements in treatment, bleeding episodes persist, significantly impacting physical health and quality of life (QoL).